{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:37:25Z","timestamp":1787881045108,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The autosomal dominant form of Alzheimer\u2019s disease (ADAD) is far less prevalent than late onset Alzheimer\u2019s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915), symptomatic mutation carriers (sMC,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098) and related noncarriers (NC,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD.\n                  <\/jats:p>","DOI":"10.1038\/srep29078","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T05:10:51Z","timestamp":1467781851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Julia","family":"Muenchhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Poljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbupalam","family":"Thalamuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veer B.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratishtha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raftery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph N.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perminder S.","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"key":"BFsrep29078_CR1","unstructured":"Wimo, A. & Prince, M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. (Alzheimer\u2019s Disease International, 2010)."},{"key":"BFsrep29078_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367, 795\u2013804 (2012).","journal-title":"N Engl J Med"},{"key":"BFsrep29078_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253\u2013260 (2014).","journal-title":"Neurology"},{"key":"BFsrep29078_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer\u2019s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 11, 1048\u20131056 (2012).","journal-title":"Lancet Neurol"},{"key":"BFsrep29078_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamaneurol.2014.1654","volume":"71","author":"JB Thomas","year":"2014","unstructured":"Thomas, J. B. et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol 71, 1111\u20131122 (2014).","journal-title":"JAMA Neurol"},{"key":"BFsrep29078_CR6","first-page":"983640","volume":"2012","author":"H Crehan","year":"2012","unstructured":"Crehan, H., Hardy, J. & Pocock, J. Microglia, Alzheimer\u2019s disease and complement. Int J Alzheimers Dis 2012, 983640 (2012).","journal-title":"Int J Alzheimers Dis"},{"key":"BFsrep29078_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415\u2013418 (2014).","journal-title":"Nat Med"},{"key":"BFsrep29078_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3233\/JAD-130380","volume":"38","author":"SJ Kiddle","year":"2014","unstructured":"Kiddle, S. J. et al. Candidate blood proteome markers of Alzheimer\u2019s disease onset and progression: a systematic review and replication study. J Alzheimers Dis 38, 515\u2013531 (2014).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep29078_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"M Sattlecker","year":"2014","unstructured":"Sattlecker, M. et al. Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10, 724\u2013734 (2014).","journal-title":"Alzheimers Dement"},{"key":"BFsrep29078_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000322229","volume":"8","author":"J Fortea","year":"2011","unstructured":"Fortea, J. et al. Cerebrospinal fluid biomarkers in Alzheimer\u2019s disease families with PSEN1 mutations. Neurodegener Dis 8, 202\u2013207 (2011).","journal-title":"Neurodegener Dis"},{"key":"BFsrep29078_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archneurol.2011.642","volume":"69","author":"JM Ringman","year":"2012","unstructured":"Ringman, J. M. et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 69, 96\u2013104 (2012).","journal-title":"Arch Neurol"},{"key":"BFsrep29078_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JAD-2012-120172","volume":"30","author":"D Wallon","year":"2012","unstructured":"Wallon, D. et al. The French series of autosomal dominant early onset Alzheimer\u2019s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis 30, 847\u2013856 (2012).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep29078_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med 6, 226\u2013230 (2014).","journal-title":"Sci Transl Med"},{"key":"BFsrep29078_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman, R. J. et al. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther 3, 1\u201313 (2011).","journal-title":"Alzheimers Res Ther"},{"key":"BFsrep29078_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1515\/revneuro-2014-0008","volume":"25","author":"JA Kamp","year":"2014","unstructured":"Kamp, J. A. et al. Amyloid beta in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Rev Neurosci 25, 641\u2013651 (2014).","journal-title":"Rev Neurosci"},{"key":"BFsrep29078_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1538-7836.2007.02516.x","volume":"5","author":"JC Rau","year":"2007","unstructured":"Rau, J. C., Beaulieu, L. M., Huntington, J. A. & Church, F. C. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5 Suppl 1, 102\u2013115 (2007).","journal-title":"J Thromb Haemost"},{"key":"BFsrep29078_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/ars.2009.2787","volume":"12","author":"E Tolosano","year":"2010","unstructured":"Tolosano, E., Fagoonee, S., Morello, N., Vinchi, F. & Fiorito, V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal 12, 305\u2013320 (2010).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep29078_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.febslet.2012.03.002","volume":"586","author":"CA Hu","year":"2012","unstructured":"Hu, C. A., Klopfer, E. I. & Ray, P. E. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett 586, 947\u2013955 (2012).","journal-title":"FEBS Lett"},{"key":"BFsrep29078_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0000000000000721","volume":"83","author":"E McDade","year":"2014","unstructured":"McDade, E. et al. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 83, 710\u2013717 (2014).","journal-title":"Neurology"},{"key":"BFsrep29078_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3233\/JAD-141266","volume":"43","author":"J Muenchhoff","year":"2015","unstructured":"Muenchhoff, J. et al. Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease across two independent cohorts. J Alzheimers Dis 43, 1355\u20131373 (2015).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep29078_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-5956-12-5","volume":"12","author":"F Song","year":"2014","unstructured":"Song, F. et al. Plasma protein profiling of Mild Cognitive Impairment and Alzheimer\u2019s disease using iTRAQ quantitative proteomics. Proteome Sci 12, 5 (2014).","journal-title":"Proteome Sci"},{"key":"BFsrep29078_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/prca.200780101","volume":"2","author":"P Cutler","year":"2008","unstructured":"Cutler, P. et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer\u2019s disease in human plasma. Proteomics Clin Appl 2, 467\u2013477 (2008).","journal-title":"Proteomics Clin Appl"},{"key":"BFsrep29078_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-121474","volume":"34","author":"A Rembach","year":"2013","unstructured":"Rembach, A. et al. Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer\u2019s Disease. J Alzheimers Dis 34, 171\u2013182 (2013).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep29078_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-122074","volume":"34","author":"SE O\u2019Bryant","year":"2013","unstructured":"O\u2019Bryant, S. E. et al. Biomarkers of Alzheimer\u2019s disease among Mexican Americans. J Alzheimers Dis 34, 841\u2013849 (2013).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep29078_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.neuroimage.2014.08.041","volume":"102","author":"A Nazeri","year":"2014","unstructured":"Nazeri, A. et al. Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer\u2019s disease. Neuroimage 102 Pt 2, 657\u2013665 (2014).","journal-title":"Neuroimage"},{"key":"BFsrep29078_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbadis.2008.08.006","volume":"1782","author":"BR Whatley","year":"2008","unstructured":"Whatley, B. R., Li, L. & Chin, L. S. The ubiquitin-proteasome system in spongiform degenerative disorders. Biochim Biophys Acta 1782, 700\u2013712 (2008).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep29078_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MCA.0b013e3283155579","volume":"19","author":"SS Huang","year":"2008","unstructured":"Huang, S. S. et al. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. Coron Artery Dis 19, 597\u2013602 (2008).","journal-title":"Coron Artery Dis"},{"key":"BFsrep29078_CR28","doi-asserted-by":"publisher","first-page":"34256","DOI":"10.1074\/jbc.M112.353532","volume":"287","author":"Y Ikeda","year":"2012","unstructured":"Ikeda, Y. et al. Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. J Biol Chem 287, 34256\u201334263 (2012).","journal-title":"J Biol Chem"},{"key":"BFsrep29078_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5551\/jat.1552","volume":"16","author":"K Aihara","year":"2009","unstructured":"Aihara, K., Azuma, H., Akaike, M., Sata, M. & Matsumoto, T. Heparin cofactor II as a novel vascular protective factor against atherosclerosis. J Atheroscler Thromb 16, 523\u2013531 (2009).","journal-title":"J Atheroscler Thromb"},{"key":"BFsrep29078_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","volume":"76","author":"VB Gupta","year":"2011","unstructured":"Gupta, V. B. et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091\u20131098 (2011).","journal-title":"Neurology"},{"key":"BFsrep29078_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4155\/cli.12.93","volume":"2","author":"JC Morris","year":"2012","unstructured":"Morris, J. C. et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig 2, 975\u2013984 (2012).","journal-title":"Clin Investig"},{"key":"BFsrep29078_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.nic.2005.09.008","volume":"15","author":"SG Mueller","year":"2005","unstructured":"Mueller, S. G. et al. The Alzheimer\u2019s disease neuroimaging initiative. Neuroimaging Clin N Am 15, 869\u2013877 (2005).","journal-title":"Neuroimaging Clin N Am"},{"key":"BFsrep29078_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G Mckhann","year":"1984","unstructured":"Mckhann, G. et al. Clinical-Diagnosis of Alzheimers-Disease - Report of the Nincds-Adrda Work Group under the Auspices of Department-of-Health-and-Human-Services Task-Force on Alzheimers-Disease. Neurology 34, 939\u2013944 (1984).","journal-title":"Neurology"},{"key":"BFsrep29078_CR34","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"BFsrep29078_CR35","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1001\/jama.1993.03500180078038","volume":"269","author":"RM Crum","year":"1993","unstructured":"Crum, R. M., Anthony, J. C., Bassett, S. S. & Folstein, M. F. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 2386\u20132391 (1993).","journal-title":"JAMA"},{"key":"BFsrep29078_CR36","unstructured":"Wechsler, D. Manual: Wechsler Memory Scale - Revised. (Psychological Corporation, 1987)."},{"key":"BFsrep29078_CR37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z","volume":"17","author":"P Burton","year":"1998","unstructured":"Burton, P., Gurrin, L. & Sly, P. Extending the simple linear regression model to account for correlated responses: An introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 17, 1261\u20131291 (1998).","journal-title":"Stat Med"},{"key":"BFsrep29078_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v015.i02","volume":"15","author":"U Halekoh","year":"2006","unstructured":"Halekoh, U., Hojsgaard, S. & Yan, J. The R Package geepack for Generalized Estimating Equations. J Stat Softw 15, 1\u201311 (2006).","journal-title":"J Stat Softw"},{"key":"BFsrep29078_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.1650","volume":"23","author":"J Yan","year":"2004","unstructured":"Yan, J. & Fine, J. Estimating equations for association structures. Stat Med 23, 859\u2013874 (2004).","journal-title":"Stat Med"},{"key":"BFsrep29078_CR40","unstructured":"Dabney, A. & Storey, J. D. qvalue: Q-value estimation for false discovery rate control. R package version 1.34.0."},{"key":"BFsrep29078_CR41","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey, J. D. & Tibshirani, R. Statistical significance for genome-wide experiments. Proc Natl Acad Sci USA 100, 9440\u20139445 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep29078_CR42","doi-asserted-by":"publisher","first-page":"D808","DOI":"10.1093\/nar\/gks1094","volume":"41","author":"A Franceschini","year":"2013","unstructured":"Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41, D808\u2013815 (2013).","journal-title":"Nucleic Acids Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep29078","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:49:52Z","timestamp":1672836592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep29078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep29078"],"URL":"https:\/\/doi.org\/10.1038\/srep29078","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]},"assertion":[{"value":"22 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Bateman received research grants from Pharma Consortium (Biogen  Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-Roche Inc., Genentech Inc., Janssen Alzheimer  Immunotherapy, Mithridion Inc., Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, Eisai)  and is co-founder and part-owner of C2N. There are no conflicts relevant to this manuscript. Dr. Fagan is  a member of the scientific advisory boards of IBL International and Roche and is a consultant for AbbVie,  Novartis and DiamiR. There are no conflicts relevant to this manuscript. The other authors declare no potential  conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29078"}}